Adipose‐Derived Mesenchymal Stem Cells: Isolation, Origin, Phenotype Applications, and Challenges
4 affiliations
- 1Department of Plastic Surgery, Chongqing Emergency Medical Center Chongqing University Central Hospital, School of Medicine, Chongqing University Chongqing China
- 2Department of Intensive Care Medicine, Chongqing Emergency Medical Center Chongqing University Central Hospital, School of Medicine, Chongqing University Chongqing China
- 3Department of Cardiothoracic Surgery, Chongqing Emergency Medical Center Chongqing University Central Hospital, School of Medicine, Chongqing University Chongqing China
- 4Department of Intensive Care Medicine Chongqing Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Chongqing China
Abstract
Traditional adipose‐derived mesenchymal stem cells (AD‐MSCs) research has relied on unfractionated bulk populations, whose therapeutic efficacy is constrained by cellular heterogeneity, culture‐induced phenotypic drift, and rapid postengraftment functional exhaustion, resulting in inconsistent outcomes and impeding clinical translation. This review systematically examines AD‐MSC developmental origins, tissue niches, isolation and purification strategies, functional phenotypes, and biomanufacturing bottlenecks. It integrates preclinical and clinical evidence for AD‐MSCs and their extracellular vesicles (EVs) in bone and cartilage regeneration, chronic cutaneous diseases, neurological disorders, cardiovascular diseases, and other conditions. These therapies remodel injured microenvironments through immunometabolic reprogramming, antifibrotic signaling, angiogenesis, mitochondrial transfer, and paracrine regulation rather than direct tissue replacement. Major translational barriers include cellular heterogeneity, safety concerns, the transdifferentiation controversy, nonstandardized preconditioning, culture‐induced phenotypic drift, and low cell retention after transplantation. We propose that clinical translation should be based on prospective isolation of functional subpopulations, coupled with tailored preconditioning, precision gene editing, three‐dimensional biomaterials, EV engineering, and automated closed‐system biomanufacturing. This framework aims to preserve potency, phenotypic stability, and paracrine function, transforming AD‐MSCs and their bioactive derivatives from variable, unfractionated preparations into well‐characterized, standardized, highly potent precision biologics. More broadly, it offers a mechanism‐driven, function‐defined, engineering‐enabled, and clinically accessible roadmap for next‐generation regenerative medicine.
Related
- Biochemical profiling of adipose-derived mesenchymal stem cell conditioned media: Reproducible protein quantification and growth factor analysis
- Direct 3D isolation in gelatin methacryloyl microbeads versus conventional 2D isolation and culture: a trade-off between mesenchymal stromal cell purity and niche-associated transcriptional profiles
- Isolation, identification, and slow-growth phenotype characterization of a clinically derived Escherichia coli from urinary tract infection
- Mesenchymal stromal cells for progressive multiple sclerosis: current evidence and translational challenges
- Nano-enabled microbial bioinputs for sustainable agriculture: advances, mechanisms, applications, and future challenges
BibTeX
@article{liu2026adiposederived,
title = {{Adipose‐Derived Mesenchymal Stem Cells: Isolation, Origin, Phenotype Applications, and Challenges}},
author = {Ziyang Liu and Guangming Tu and Chao Wang and Hongyan Zhao and Ziyi Wu and Wei Li and Li Chen and Bailin Niu},
journal = {MedComm},
year = {2026},
month = nov,
doi = {10.1002/mco2.71103},
url = {https://doi.org/10.1002/mco2.71103},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Adipose‐Derived Mesenchymal Stem Cells: Isolation, Origin, Phenotype Applications, and Challenges
AU - Ziyang Liu
AU - Guangming Tu
AU - Chao Wang
AU - Hongyan Zhao
AU - Ziyi Wu
AU - Wei Li
AU - Li Chen
AU - Bailin Niu
PY - 2026
DA - 2026/11/03
JO - MedComm
DO - 10.1002/mco2.71103
UR - https://doi.org/10.1002/mco2.71103
AB - Traditional adipose‐derived mesenchymal stem cells (AD‐MSCs) research has relied on unfractionated bulk populations, whose therapeutic efficacy is constrained by cellular heterogeneity, culture‐induced phenotypic drift, and rapid postengraftment functional exhaustion, resulting in inconsistent outcomes and impeding clinical translation. This review systematically examines AD‐MSC developmental origins, tissue niches, isolation and purification strategies, functional phenotypes, and biomanufacturing bottlenecks. It integrates preclinical and clinical evidence for AD‐MSCs and their extracellular vesicles (EVs) in bone and cartilage regeneration, chronic cutaneous diseases, neurological disorders, cardiovascular diseases, and other conditions. These therapies remodel injured microenvironments through immunometabolic reprogramming, antifibrotic signaling, angiogenesis, mitochondrial transfer, and paracrine regulation rather than direct tissue replacement. Major translational barriers include cellular heterogeneity, safety concerns, the transdifferentiation controversy, nonstandardized preconditioning, culture‐induced phenotypic drift, and low cell retention after transplantation. We propose that clinical translation should be based on prospective isolation of functional subpopulations, coupled with tailored preconditioning, precision gene editing, three‐dimensional biomaterials, EV engineering, and automated closed‐system biomanufacturing. This framework aims to preserve potency, phenotypic stability, and paracrine function, transforming AD‐MSCs and their bioactive derivatives from variable, unfractionated preparations into well‐characterized, standardized, highly potent precision biologics. More broadly, it offers a mechanism‐driven, function‐defined, engineering‐enabled, and clinically accessible roadmap for next‐generation regenerative medicine.
SN - 2688-2663
ER -